Junwei Gao

Junwei Gao

Auto-generated profile, based on publicly available information

Junwei Gao

Department of Nephrology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JGJunwei Gao
Junwei Gao
PLPeng Liu
Peng Liu
ZSZhengri Shen
Zhengri Shen
KXKe Xu
Ke Xu
CWChenguang Wu
Chenguang Wu
PLPing Li
Ping Li
Lipid deposition is an etiology of renal damage caused by lipid metabolism disorder in diabetic nephropathy (DN). Thus, reducing lipid deposition is a feasible strategy for the treatment of DN. Morroniside (MOR), an iridoid glycoside isolated from the Chinese herb Cornus officinalis Sieb. et Zucc., is considered to be an effective drug in inhibiting oxidative stress, reducing inflammatory response, and countering apoptosis. To explore the protective mechanism of MOR in attenuating renal lipotoxicity in DN, we investigated the effect of MOR on an in vitro model of lipid metabolism disorder of DN established by stimulating mouse renal tubular epithelial cells (mRTECs) with sodium palmitate (PA) or high glucose (HG). Oil Red O and filipin cholesterol staining assays were used to determine intracellular lipid accumulation status. Results revealed that PA or HG stimulation inhibited the expressions of peroxisome proliferator‐activated receptor γ coactivator 1α (PGC‐1α), liver X receptors (LXR), ATP‐binding cassette subfamily A member 1 (ABCA1), ABCG1, and apolipoprotein E (ApoE) in mRTECs as evidenced by western blot and quantitative real‐time PCR, resulting in increased intracellular lipid deposition. Interestingly, MOR upregulated expressions of PGC‐1α, LXR, ABCA1, ABCG1, and ApoE, thus reducing cholesterol accumulation in mRTECs, suggesting that MOR might promote cholesterol efflux from mRTECs via the PGC‐1α/LXR pathway. Of note, silencing PGC‐1α reversed the promotive effect of MOR on PA‐ or HG‐induced cellular cholesterol accumulation. In conclusion, our results suggest that MOR has a protective effect on mRTECs under high lipid or high glucose conditions, which may be related to the promotion of intracellular cholesterol efflux mediated by PGC‐1α.

30 September 2026 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YWYunzhou Wu
Yunzhou Wu
JGJunwei Gao
Junwei Gao
JLJiazhen Lin
Jiazhen Lin
JXJie Xing
Jie Xing
XCXudong Cai
Xudong Cai
Diabetic Kidney Disease (DKD), a prevalent microvascular complication of diabetes mellitus, represents the leading cause of end-stage renal disease worldwide. Its pathogenesis is multifactorial, involving metabolic disturbances, oxidative stress, inflammatory responses, and notably, mitochondrial dysfunction. Mitochondria, as the primary energy-producing organelles, undergo morphological and functional impairment under hyperglycemic conditions, including excessive reactive oxygen species generation, aberrant dynamics (fusion/fission imbalance), defective mitophagy, reduced biogenesis, and activation of mitochondria-mediated apoptosis. These interconnected abnormalities contribute to glomerular and tubular injury, ultimately promoting renal fibrosis and functional decline. Emerging evidence highlights the therapeutic potential of natural products—such as flavonoids, polyphenols, alkaloids, and saponins—in restoring mitochondrial homeostasis through multitarget mechanisms. These compounds activate the Nrf2/ARE and AMPK/SIRT1/PGC- 1α pathways to enhance antioxidant defense and promote mitochondrial biogenesis; regulate Drp1/Mfn1/2/OPA1 to restore mitochondrial dynamics; induce PINK1/Parkin- or BNIP3-mediated mitophagy to clear dysfunctional mitochondria; and modulate Bcl-2/Bax/caspase signaling to suppress apoptosis. Despite robust preclinical efficacy, clinical translation is hindered by poor bioavailability, batch-to-batch variability, lack of standardized formulations, and limited high-quality trials with mitochondrial-specific endpoints. Advances in kidney-targeted nanodelivery systems and AIdriven compound screening offer promising strategies to overcome these barriers. This review synthesizes current knowledge on the mechanisms by which natural products alleviate mitochondrial dysfunction in DKD, evaluates translational challenges, and proposes future directions for developing these compounds into adjunctive therapies.